Propranolol Accord 40 mg Norge - norsk - Statens legemiddelverk

propranolol accord 40 mg

accord healthcare b.v. - propranololhydroklorid - tablett, filmdrasjert - 40 mg

Pranolol 40 mg Norge - norsk - Statens legemiddelverk

pranolol 40 mg

actavis group ptc ehf (1) - propranololhydroklorid - tablett - 40 mg

Propranolol Accord 10 mg Norge - norsk - Statens legemiddelverk

propranolol accord 10 mg

accord healthcare b.v. - propranololhydroklorid - tablett, filmdrasjert - 10 mg

Propranolol Accord 80 mg Norge - norsk - Statens legemiddelverk

propranolol accord 80 mg

accord healthcare b.v. - propranololhydroklorid - tablett, filmdrasjert - 80 mg

Pranolol 20 mg Norge - norsk - Statens legemiddelverk

pranolol 20 mg

actavis group ptc ehf (1) - propranololhydroklorid - tablett - 20 mg

Pranolol 80 mg Norge - norsk - Statens legemiddelverk

pranolol 80 mg

actavis group ptc ehf (1) - propranololhydroklorid - tablett - 80 mg

Hemangiol Den europeiske union - norsk - EMA (European Medicines Agency)

hemangiol

pierre fabre medicament - propranolol hydroklorid - hemangiom - betablokkende midler - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

Namuscla Den europeiske union - norsk - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic lidelser - hjertetapi - namuscla er indikert for symptomatisk behandling av myotonia hos voksne pasienter med ikke-dystrophic myotonic lidelser.

Rimstar Norge - norsk - Statens legemiddelverk

rimstar

sandoz - københavn - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg

Zeposia Den europeiske union - norsk - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.